Fighting Virus Pandemics: The Now and The Future - Expert’s Perception of Challenges & Opportunities
APR 1 2020
Moderator:
Dr. Shawn Shi, Venture Partner at MSQ
Invited guests:
Mr. Mark Engel, Chairman and CEO at Phagelux
About Phagelux:
Phagelux utilizes phages, lysins and other biologics and related delivery technologies to create novel antibacterial products and solutions. Phagelux particularly targets anti-microbial resistant pathogens. It has R&D centers in Montreal, Canada and Wuhan, China. The former is focused on bacteriophage products while the latter develops lysin products.
For more information, please visit here.